Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study
Sponsor: Celgene
This PHASE2 trial investigates Multiple Myeloma and is currently completed. Celgene leads this study, which shows 10 recorded versions since 2011 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Jun 2019 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
- National Cancer Institute (NCI)
- Onyx Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .